Literature DB >> 20835647

The interaction between aromatase, metalloproteinase 2,9 and CD44 in breast cancer.

Fábio Bagnoli1, Vilmar Marques de Oliveira, Maria Antonieta Longo Galvão da Silva, Giuliana Cássia Morrone Taromaru, José Francisco Rinaldi, Tsutomu Aoki.   

Abstract

OBJECTIVE: This study intends to verify the expression levels and correlation of aromatase, matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9) and CD44 in ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC) when both are found in the same breast.
METHODS: One hundred and ten cases were evaluated by tissue microarray (TMA) and immunohistochemically screened with anti-aromatase polyclonal antibodies, anti-MMP-2 monoclonal antibodies, anti-MMP-9 polyclonal antibodies and anti-CD44 monoclonal antibodies.
RESULTS: Aromatase was expressed in IDC and DCIS in 63 (57.3%) and 60 (67%) of the cases respectively; MMP-2 was similarly expressed in IDC and DCIS in 15 (13.60%) cases; MMP-9 was positively expressed in IDC and DCIS in 83 (75.50%) and 82 (74.50%) cases, respectively; CD44 was positively expressed in IDC and DCIS in 49 (44.50%) and 48 (42.60%) of the cases, respectively; all of them were highly correlated (p<0,001). The correlation analysis found positive, statistically significant correlation, in IDC between aromatase and MMP-2 (p<0.001) and between aromatase and MMP-9 (p=0.034). Positive correlation between aromatase and MMP-2 (p<0.001) and between MMP-9 and CD44 (p=0.030) were found in DCIS.
CONCLUSION: These results allow us to conclude that aromatase through local estrogen synthesis in breast tissue plays an important role in breast carcinogenesis, mainly influencing MMP-2 and MMP-9 which are important participants in tumor cell invasion and dependence of their connection to CD44 for action.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20835647     DOI: 10.1590/s0104-42302010000400023

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  6 in total

Review 1.  Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.

Authors:  Song Xia; Qiong Lin
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 2.  An overview of recently published medical papers in Brazilian scientific journals.

Authors:  Mauricio Rocha e Silva; Ariane Gomes
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 3.  Post-menopausal breast cancer: from estrogen to androgen receptor.

Authors:  Avisek Majumder; Mahavir Singh; Suresh C Tyagi
Journal:  Oncotarget       Date:  2017-10-27

4.  CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion.

Authors:  Allal Ouhtit; Mohammed E Abdraboh; Andrew D Hollenbach; Hatem Zayed; Madhwa H G Raj
Journal:  Cell Commun Signal       Date:  2017-11-09       Impact factor: 5.712

5.  Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.

Authors:  Nazli Bahrami; Shakila Jabeen; Andliena Tahiri; Torill Sauer; Hilde Presterud Ødegård; Stephanie Beate Geisler; Berit Gravdehaug; Laurens Cornelus Reitsma; Knut Selsås; Vessela Kristensen; Jürgen Geisler
Journal:  Breast Cancer Res Treat       Date:  2021-09-23       Impact factor: 4.872

Review 6.  CD44: A Multifunctional Mediator of Cancer Progression.

Authors:  Malak Hassn Mesrati; Saiful Effendi Syafruddin; M Aiman Mohtar; Amir Syahir
Journal:  Biomolecules       Date:  2021-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.